Integrative, high-resolution analysis of single cells across experimental conditions with PARAFAC2.
Andrew RamirezBrian T Orcutt-JahnsSean PascoeArmaan AbrahamBreanna RemigioNathaniel ThomasAaron S MeyerPublished in: bioRxiv : the preprint server for biology (2024)
Effective tools for exploration and analysis are needed to extract insights from large-scale single-cell measurement data. However, current techniques for handling single-cell studies performed across experimental conditions (e.g., samples, perturbations, or patients) require restrictive assumptions, lack flexibility, or do not adequately deconvolute condition-to-condition variation from cell-to-cell variation. Here, we report that the tensor decomposition method PARAFAC2 (Pf2) enables the dimensionality reduction of single-cell data across conditions. We demonstrate these benefits across two distinct contexts of single-cell RNA-sequencing (scRNA-seq) experiments of peripheral immune cells: pharmacologic drug perturbations and systemic lupus erythematosus (SLE) patient samples. By isolating relevant gene modules across cells and conditions, Pf2 enables straightforward associations of gene variation patterns across specific patients or perturbations while connecting each coordinated change to certain cells without pre-defining cell types. The theoretical grounding of Pf2 suggests a unified framework for many modeling tasks associated with single-cell data. Thus, Pf2 provides an intuitive universal dimensionality reduction approach for multi-sample single-cell studies across diverse biological contexts.
Keyphrases
- single cell
- rna seq
- systemic lupus erythematosus
- high throughput
- induced apoptosis
- end stage renal disease
- cell cycle arrest
- ejection fraction
- chronic kidney disease
- electronic health record
- peritoneal dialysis
- emergency department
- genome wide
- big data
- disease activity
- gene expression
- signaling pathway
- endoplasmic reticulum stress
- dna methylation
- machine learning
- cell death
- rheumatoid arthritis
- data analysis
- mass spectrometry
- patient reported
- artificial intelligence
- adverse drug